{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:25:24Z","timestamp":1790889924886,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"s6","license":[{"start":{"date-parts":[[2006,11,10]],"date-time":"2006-11-10T00:00:00Z","timestamp":1163116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Risk factors for inhibitor development include specific factor VIII (FVIII) genotypes, a family history of inhibitor development amongst first\u2010degree relatives, certain HLA haplotypes and non\u2010caucasian ethnicity. Patients with major FVIII deletions or rearrangements have a higher risk of inhibitor development than those with small deletions or missense mutations. Studies of HLA\u2010DR amongst northern European patients with the intron 22 inversion indicate that certain HLA haplotypes may also confer either increased or decreased inhibitor risk. However, although brothers of patients with inhibitor have a high risk of inhibitor development, concordance is not 100%, and other constitutional factors must also operate. Disputed risk factors for inhibitor development include early age at first FVIII exposure, the use of recombinant rather than plasma\u2010derived FVIII and product switching. Two studies suggest that inhibitor risk is increased by very early FVIII exposure (<jats:italic>P<\/jats:italic>\u2003=\u20030.03), but this is disputed by a third study; larger studies addressing the question are ongoing. Studies investigating the relative inhibitor risk of plasma\u2010derived vs. recombinant FVIII have been similarly inconclusive and will be reviewed. Other environmental or treatment variables such as concomitant infection or vaccination are suspected to influence inhibitor risk but have not yet been fully investigated.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2006.01362.x","type":"journal-article","created":{"date-parts":[[2006,11,10]],"date-time":"2006-11-10T14:06:14Z","timestamp":1163167574000},"page":"23-29","source":"Crossref","is-referenced-by-count":53,"title":["The epidemiology of factor VIII inhibitors"],"prefix":"10.1111","volume":"12","author":[{"given":"CHARLES R. M.","family":"HAY","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,11,10]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08435.x"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91593-B"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90874-3"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302183280701"},{"key":"e_1_2_4_6_2","first-page":"2428","article-title":"A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group","volume":"83","author":"Bray GL","year":"1994","journal-title":"Blood"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615061"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.2.344.344"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1648507"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(77)90089-7"},{"key":"e_1_2_4_11_2","first-page":"45","article-title":"Genetic predisposition to inhibitor formation","volume":"150","author":"Shapiro SS","year":"1984","journal-title":"Prog Clin Biol Res"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00510.x"},{"key":"e_1_2_4_13_2","first-page":"500","article-title":"The role of genetics in inhibitor formation","volume":"2","author":"Gill JC","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_14_2","first-page":"924","article-title":"The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A","volume":"90","author":"Astermark J","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01119.x"},{"key":"e_1_2_4_16_2","first-page":"19","volume-title":"Factor VIII Inhibitors","author":"Gill FM","year":"1984"},{"key":"e_1_2_4_17_2","first-page":"293a","article-title":"Increased frequency of inhibitors in African American hemophilic patients","volume":"1","author":"Addiego JE","year":"1994","journal-title":"Blood"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00300.x"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1371"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05605.x"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655944"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655945"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3918"},{"key":"e_1_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00451.x"},{"key":"e_1_2_4_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00655.x"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02828.x"},{"key":"e_1_2_4_27_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1055\/s-0037-1613376","article-title":"First treatment and immune tolerance to factor VIII in severe hemophilia","volume":"89","author":"Van der Bom JG","year":"2003","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00230.x"},{"key":"e_1_2_4_29_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1361.094"},{"key":"e_1_2_4_30_2","first-page":"266a","article-title":"Higher immune tolerance (IT) success rate with monoclonal FVIII (mFVIII) when compared to recombinant (rFVIII): An analysis of The North American Immune Tolerance Registry (NAITR)","volume":"96","author":"DiMichele D","year":"2000","journal-title":"Blood"},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-32664"},{"key":"e_1_2_4_32_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615358"},{"key":"e_1_2_4_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00780.x"},{"key":"e_1_2_4_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830240303"},{"key":"e_1_2_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb06370.x"},{"key":"e_1_2_4_36_2","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1182\/blood.V81.12.3332.3332","article-title":"Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophylised cryoprecipitate","volume":"81","author":"Peerlinck K","year":"1993","journal-title":"Blood"},{"key":"e_1_2_4_37_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1653753"},{"key":"e_1_2_4_38_2","first-page":"997","article-title":"Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex","volume":"73","author":"Schimpf K","year":"1995","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_39_2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1055\/s-0038-1657681","article-title":"Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product","volume":"78","author":"Yee TT","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_40_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH03-10-0643"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2006.01362.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2006.01362.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T12:19:24Z","timestamp":1695730764000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2006.01362.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,10]]},"references-count":39,"journal-issue":{"issue":"s6","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1111\/j.1365-2516.2006.01362.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2006.01362.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,10]]}}}